ストックスクリーナーアプリを入手
240.98
0.87%
-2.12
前日終値:
$243.10
開ける：
$242.02
24時間の取引高:
812.90K
Relative Volume:
0.63
時価総額：
$35.61B
収益：
$9.60B
当期純損益:
$1.37B
株価収益率:
25.86
EPS:
9.3182
ネットキャッシュフロー:
$2.32B
1週間 パフォーマンス:
+2.39%
1か月 パフォーマンス:
+6.93%
6か月 パフォーマンス:
+26.78%
1年 パフォーマンス:
+63.13%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$231.04
$244.65
52週間の値動き範囲:
$138.00
$244.65
Biogen Inc Stock (BIIB) Company Profile
Compare BIIB vs LLY, JNJ, ABBV, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
240.98 | 35.61B | 9.60B | 1.37B | 2.32B | 9.3182 |
LLY
Lilly Eli Co
|
1,270.75 | 1.13T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
257.78 | 621.22B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
284.80 | 503.28B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
149.88 | 369.78B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.93 | 292.58B | 54.66B | 13.58B | 16.05B | 7.0171 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-10-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2026-08-13 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2026-07-13 | アップグレード | Truist | Hold → Buy |
| 2026-06-08 | アップグレード | Needham | Hold → Buy |
| 2026-05-15 | 再開されました | Evercore ISI | Outperform |
| 2026-04-22 | アップグレード | UBS | Neutral → Buy |
| 2026-04-20 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2026-04-14 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2026-02-20 | 開始されました | Barclays | Equal Weight |
| 2026-02-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2026-01-07 | 再開されました | UBS | Neutral |
| 2025-12-10 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2025-11-06 | アップグレード | Stifel | Hold → Buy |
| 2025-09-25 | 開始されました | Jefferies | Buy |
| 2025-07-21 | 再開されました | Truist | Hold |
| 2025-04-28 | ダウングレード | HSBC Securities | Buy → Hold |
| 2025-04-04 | ダウングレード | Argus | Buy → Hold |
| 2025-02-11 | 開始されました | Bernstein | Mkt Perform |
| 2025-01-02 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | ダウングレード | Stifel | Buy → Hold |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-12-09 | ダウングレード | Jefferies | Buy → Hold |
| 2024-11-18 | ダウングレード | Needham | Buy → Hold |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-11-14 | 開始されました | Citigroup | Neutral |
| 2024-10-31 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-02-14 | 繰り返されました | Needham | Buy |
| 2024-02-14 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | ダウングレード | UBS | Buy → Neutral |
| 2023-12-20 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-12-07 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | 開始されました | HSBC Securities | Buy |
| 2023-07-27 | 開始されました | Scotiabank | Sector Outperform |
| 2023-07-24 | 繰り返されました | UBS | Buy |
| 2023-05-01 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-04-17 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | アップグレード | Goldman | Neutral → Buy |
| 2022-10-13 | アップグレード | Stifel | Hold → Buy |
| 2022-10-07 | アップグレード | Argus | Hold → Buy |
| 2022-09-28 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | アップグレード | Mizuho | Neutral → Buy |
| 2022-09-28 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | ダウングレード | Stifel | Buy → Hold |
| 2022-03-03 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | 繰り返されました | Barclays | Equal Weight |
| 2022-02-04 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-04 | 繰り返されました | Cowen | Outperform |
| 2022-02-04 | 繰り返されました | Morgan Stanley | Overweight |
| 2022-02-04 | 繰り返されました | Needham | Buy |
| 2022-02-04 | 繰り返されました | Oppenheimer | Outperform |
| 2022-02-04 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | 繰り返されました | Robert W. Baird | Neutral |
| 2022-02-04 | 繰り返されました | Wedbush | Neutral |
| 2022-02-04 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-02-04 | 繰り返されました | Wolfe Research | Peer Perform |
| 2022-01-13 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-01-12 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | 再開されました | Raymond James | Mkt Perform |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-09-23 | 開始されました | Needham | Buy |
| 2021-06-18 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | 繰り返されました | Truist | Buy |
| 2021-06-11 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | アップグレード | UBS | Neutral → Buy |
| 2021-06-08 | アップグレード | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | 繰り返されました | Barclays | Equal Weight |
| 2021-06-08 | アップグレード | Citigroup | Sell → Neutral |
| 2021-06-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-06-08 | 繰り返されました | Jefferies | Buy |
| 2021-06-08 | 繰り返されました | Morgan Stanley | Overweight |
| 2021-06-08 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | アップグレード | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | 繰り返されました | Stifel | Buy |
| 2021-06-08 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | アップグレード | BofA Securities | Underperform → Neutral |
| 2021-06-07 | アップグレード | Cowen | Market Perform → Outperform |
| 2021-06-07 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | ダウングレード | DZ Bank | Buy → Hold |
| 2021-01-29 | アップグレード | Stifel | Hold → Buy |
| 2020-11-10 | アップグレード | DZ Bank | Hold → Buy |
| 2020-11-09 | ダウングレード | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-11-09 | ダウングレード | Cowen | Outperform → Market Perform |
| 2020-11-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-11-04 | アップグレード | BofA Securities | Underperform → Neutral |
| 2020-11-04 | アップグレード | Jefferies | Hold → Buy |
| 2020-11-04 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-07-27 | アップグレード | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2020-06-22 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | ダウングレード | Citigroup | Neutral → Sell |
| 2020-04-23 | ダウングレード | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | 開始されました | Wolfe Research | Peer Perform |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2020-01-27 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | ダウングレード | Robert W. Baird | Neutral → Underperform |
すべてを表示
Biogen Inc (BIIB) 最新ニュース
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Zacks Investment Research
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now - Zacks Investment Research
AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results - Zacks Investment Research
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now? - Zacks Investment Research
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? - Zacks Investment Research
Cisco Systems (CSCO) Stock Price, News & Analysis - 24/7 Wall St.
Lori Trahan Stock Trades and Disclosures - TechGraph
Daniel S Sullivan Stock Trades and Disclosures - TechGraph
Daniel S Sullivan Stock Trades and Disclosures - TechGraph
Form 4 Boeing Co For: 7 October By Investing.com - Investing.com UK
Brookfield Renewable Partners (BEP) Stock Price, News & Analysis - 24/7 Wall St.
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research
Cisco Systems Surges 4.2% to $118.31 in a Single Session - 24/7 Wall St.
Biogen's Chief Accounting Officer Sean Godbout Reports October 2026 Stock Transactions via Form 4 - Kalkine Media
Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise? - Zacks Investment Research
Form 4 Boeing Co For: 26 September - Investing.com India
Boeing Company (BA) Stock News & Articles - 247wallst.com
Biogen Inc. (BIIB) Stock Price, News, Quote & History - Yahoo! Finance Canada
Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook - The Motley Fool
Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology - Yahoo Finance
Biogen (BIIB) Sees Canada Back LEQEMBI As Fair Value Stays In Focus - simplywall.st
Biogen (BIIB) Sees Canada Back LEQEMBI As Fair Value Stays In Focus - simplywall.st
Alzheimer’s Disease Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Alpha Cognition, Biogen, Eisai, Eli Lilly, Otsuka Pharma, Lundbeck, Suven Life Sciences, Roche - Barchart.com
Multiple Sclerosis Market Outlook 2036: Growth Trends, Competitive Landscape, and Future Opportunities by 2034 – DelveInsight | Biogen, Immune Response BioPharma, ImCyse, Atara Bio, Emerald Health - Barchart.com
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
BIIB Maintained by HSBC -- Price Target Raised to $175 - GuruFocus
Biogen Inc. stock gains on fresh analyst upgrades and strong Q2 figures - ad-hoc-news.de
Stifel reiterates Biogen stock rating on immunology pipeline - investing.com
Stifel reiterates Biogen stock rating on immunology pipeline By Investing.com - Investing.com Canada
Stifel reiterates Biogen stock rating on immunology pipeline - Investing.com
Can Biogen (NASDAQ:BIIB) Stay Resilient As Inflation Rises? - Kalkine Media
Biogen at Wells Fargo healthcare conference: growth bets widen By Investing.com - Investing.com Canada
Biogen at Wells Fargo healthcare conference: growth bets widen By Investing.com - Investing.com India
Biogen Inc. at Wells Fargo Healthcare Conference Transcript - GuruFocus
Learn Why The Bull Case For Biogen Stock Could Change Following Canada Reimbursement Backing - simplywall.st
Learn Why The Bull Case For Biogen Stock Could Change Following Canada Reimbursement Backing - simplywall.st
Monoclonal Antibodies Market to Grow at 11.01% CAGR, Reaching USD 791.28 Billion by 2035 – SNS Insider - GlobeNewswire Inc.
Biogen Inc (BIIB) Shares Fall 3.8% -- What GF Score of 73 Tells Investors - GuruFocus
Biogen Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Biogen Must Face Pharmacies' MS Drug Monopoly Suit - Law360
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers - Reuters
(BIIB) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Lilly Builds Neuroscience into a New Long-Term Growth Driver - Zacks Investment Research
Biogen stock heads into the open without fresh price data - ad-hoc-news.de
Drug Repurposing Market to Reach USD 50.91 Billion by 2035, Expanding at 3.93% CAGR | SNS Insider - GlobeNewswire Inc.
Biogen Inc. (BIIB) Investor Outlook: Navigating Growth in the Healthcare Sector with a Potential 7.26% Upside - DirectorsTalk Interviews
Biogen Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
Biogen Inc. stock holds near 12 month high on steady Q1 2026 growth - ad-hoc-news.de
Biogen Inc. (BIIB) Peer Comparison – Compare with Others - Value Research
Eisai, Biogen Secure China's Nod for Self-Injection Version of Leqembi - marketscreener.com
Biogen Inc (BIIB) 財務データ
収益
当期純利益
現金流量
EPS
Biogen Inc (BIIB) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Minor Lloyd | Director |
Aug 04 '26 |
Proposed Sale |
200.96 |
593 |
119,169 |
0 |
| Minor Lloyd | Director |
Aug 04 '26 |
Sale |
200.96 |
593 |
119,169 |
2,689 |
| Minor Lloyd | Director |
Aug 03 '26 |
Sale |
203.34 |
593 |
120,581 |
3,282 |
| Minor Lloyd | Director |
Aug 03 '26 |
Proposed Sale |
203.34 |
593 |
120,581 |
0 |
| Pangalos Menelas N | Director |
Jun 09 '26 |
Option Exercise |
0.00 |
2,370 |
0 |
2,370 |
| Keeney Adam | Head of Corporate Development |
May 01 '26 |
Option Exercise |
0.00 |
939 |
0 |
6,820 |
| Godbout Sean | Chief Accounting Officer |
Apr 01 '26 |
Option Exercise |
0.00 |
181 |
0 |
1,396 |
| Murphy Nicole | Head of Pharm Ops and Tech |
Feb 12 '26 |
Buy |
195.03 |
3 |
585 |
19,611 |
| Singhal Priya | Officer |
Feb 09 '26 |
Proposed Sale |
199.83 |
2,660 |
531,548 |
0 |
| Singhal Priya | Head of Development |
Feb 09 '26 |
Sale |
199.83 |
2,660 |
531,548 |
8,043 |
0.53%
0.26%
大文字化:
|
ボリューム (24 時間):